CJC-1295 has been in the peptide therapy conversation since the mid-2000s, but the published human evidence base is surprisingly small. Two peer-reviewed clinical trials and a handful of pharmacokinetic studies form most of what we actually know. The rest is mechanism inference from related drugs, anecdotal protocols from anti-aging clinics, and marketing claims that don’t trace back to published data.<\/p>\n
This review walks through what’s actually been published, what the studies showed, what they didn’t measure, and where the evidence base ends. We’ll cover the Teichman 2006 Phase 1 pharmacokinetic study, the discontinued Phase 2 trial in HIV lipodystrophy, comparator data from tesamorelin, the epidemiology of IGF-1 and disease risk, and the long-term safety data that doesn’t exist.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
Teichman et al. published “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor 1 secretion by CJC-1295” in The Journal of Clinical Endocrinology and Metabolism in 2006. This is the foundational pharmacokinetic study and the most cited paper on the drug.<\/p>\n
Quick Answer: Only two peer-reviewed human trials of CJC-1295 have been published (Teichman et al. 2006 JCEM)<\/p>\n
The trial enrolled 21 healthy adults aged 21 to 61 and tested single subcutaneous doses of 30, 60, 125, and 250 mcg\/kg. Plasma GH and IGF-1 were measured serially over 28 days. The primary findings were that a single 60 mcg\/kg dose raised mean GH 2 to 10 fold for 6 days and IGF-1 1.5 to 3 fold for 9 to 11 days.<\/p>\n
Higher doses produced larger and longer responses but more side effects. Injection site reactions occurred in 80 percent of subjects. The half-life of CJC-1295 itself was estimated at roughly 8 days based on the duration of the IGF-1 elevation.<\/p>\n
This study is the basis for the once-weekly dosing convention and the safety profile that prescribers cite. It’s also the only published data on the drug’s pharmacokinetics in healthy humans.<\/p>\n
ConjuChem ran a Phase 2 trial of CJC-1295 in HIV-associated lipodystrophy with weekly dosing of 1 to 2 mg for 12 weeks.<\/strong> The trial reported modest reductions in visceral adipose tissue and small gains in lean mass, though full results were never published in a peer-reviewed journal after the development program was discontinued.<\/p>\n The program stopped because of a patient death during a separate Phase 2 trial in lipodystrophy. The death was attributed to other causes, but ConjuChem suspended development and the drug never advanced to Phase 3 or FDA approval. The unpublished Phase 2 results were referenced in conference abstracts and company press releases at the time.<\/p>\n The lack of peer-reviewed publication means we don’t have the detail we’d need to evaluate the Phase 2 data critically. The numbers that circulate in marketing materials don’t have a citation trail to a published trial.<\/p>\n Tesamorelin is the closest analog drug with strong published evidence.<\/strong> It’s an FDA-approved GHRH analog with a shorter half-life than CJC-1295 but the same mechanism of action. The Falutz et al. 2007 NEJM trial enrolled 412 patients with HIV-associated lipodystrophy and randomized them to tesamorelin 2 mg daily or placebo for 26 weeks.<\/p>\n Tesamorelin produced a 15.2 percent reduction in visceral adipose tissue versus 5 percent increase in placebo. Lean mass increased 1.3 kg. IGF-1 rose into the upper-normal range for most patients. Side effects included injection site reactions, arthralgia, and small increases in fasting glucose.<\/p>\n These are real, published, peer-reviewed numbers. They come from a different drug than CJC-1295 but a closely related mechanism. The body composition effects of CJC-1295 in healthy adults are often extrapolated from this trial, though that extrapolation hasn’t been formally validated.<\/p>\n The most relevant comparator data comes from trials of recombinant GH in adults without diagnosed GH deficiency.<\/strong> The Liu et al. 2007 Annals of Internal Medicine meta-analysis pooled 31 randomized trials of GH in healthy older adults and found measurable but modest improvements in lean mass and reductions in fat mass.<\/p>\n The same meta-analysis documented significant increases in soft tissue edema (44 percent), arthralgia (19 percent), carpal tunnel syndrome (8 percent), and glucose intolerance (3 to 18 percent depending on trial). Functional outcomes like strength, exercise capacity, and quality of life were not consistently improved.<\/p>\n The Cohn et al. 1993 Annals of Internal Medicine trial of GH in healthy older men reported similar complication rates and noted that side effects often resolved with dose reduction. The takeaway from this literature is that raising GH\/IGF-1 in healthy adults produces small body composition changes with meaningful side effect burden.<\/p>\n Sustained IGF-1 elevation is associated with increased cancer risk in observational studies.<\/strong> Boyd et al. 2008 in the International Journal of Cancer reported that men in the highest IGF-1 quintile had roughly double the prostate cancer risk of men in the lowest quintile. Renehan et al. 2004 in The Lancet pooled data from prospective studies and found similar associations for breast and colorectal cancers.<\/p>\n These are correlations from observational epidemiology, not direct evidence that CJC-1295 causes cancer. The mechanism is plausible because IGF-1 is mitogenic and reduces apoptosis in many cell types. The clinical relevance for short-term peptide therapy is unclear because the observational data tracks lifetime IGF-1 exposure rather than 12-week elevations.<\/p>\n The conservative interpretation is that anyone with personal or strong family history of hormone-sensitive cancers should think carefully before using a drug that raises IGF-1 chronically. The evidence is suggestive enough to warrant caution.<\/p>\n No published trial has measured CJC-1295 effects on muscle strength, exercise capacity, sleep architecture, cognitive function, sexual function, recovery from injury, or any of the outcomes commonly marketed to anti-aging patients.<\/strong> The Teichman trial measured GH and IGF-1. That’s it.<\/p>\n Body composition has been measured in the discontinued Phase 2 trial but not in a peer-reviewed publication. Sleep effects, despite the popularity of bedtime dosing of the no-DAC version, have never been measured in a controlled study of CJC-1295 specifically.<\/p>\n Long-term safety beyond 28 days is unstudied. Cancer surveillance over years of use is unstudied. Effects in patients over 65 or with comorbidities are unstudied. Use in women specifically, beyond inclusion in the Phase 1 trial, is unstudied.<\/p>\n Key Takeaway: No published trials measured body composition, cancer risk, or long-term outcomes<\/p>\n The contrast is dramatic.<\/strong> STEP 1 (Wilding et al. 2021 NEJM) enrolled 1,961 patients and measured 14.9 percent weight loss over 68 weeks. SURMOUNT-1 (Jastreboff et al. 2022 NEJM) enrolled 2,539 patients and measured 20.9 percent weight loss over 72 weeks. SELECT (Lincoff et al. 2023 NEJM) showed a 20 percent reduction in major adverse cardiovascular events in 17,604 patients over a median 39.8 months.<\/p>\n These are large, long, high-quality trials with cardiovascular and metabolic outcome data. The semaglutide and tirzepatide evidence base includes tens of thousands of patient-years of exposure with rigorous safety surveillance.<\/p>\n CJC-1295 has approximately 21 patient-months of published exposure data. Apples-to-oranges comparison, but the asymmetry matters when patients are deciding what evidence-based options exist for their goals. TrimRx’s free assessment quiz can help identify which evidence-supported treatments fit specific patient situations.<\/p>\n Longevity is a common marketing claim for CJC-1295 in anti-aging contexts.<\/strong> The mechanistic argument is that restoring youthful GH and IGF-1 levels could slow age-related decline. The actual longevity evidence runs in the opposite direction.<\/p>\n GHR knockout mice live 40 to 70 percent longer than wild-type controls (Coschigano et al. 2003 Endocrinology). Long-lived human populations including Ashkenazi Jewish centenarians have lower IGF-1 levels and reduced IGF-1 receptor signaling on average (Suh et al. 2008 PNAS). Caloric restriction, the most reproducible longevity intervention in animal studies, reduces IGF-1.<\/p>\n This is the opposite of what you’d predict if raising IGF-1 promoted longevity. The current evidence base in humans and animal models suggests that lower lifetime IGF-1 exposure is associated with longer healthspan, not shorter. CJC-1295 raises IGF-1 by design. The longevity argument doesn’t survive contact with the actual evidence.<\/p>\n Bedtime dosing of CJC-1295 (typically the no-DAC version) is one of the most common protocols, with the rationale that GH amplifies slow-wave sleep.<\/strong> The mechanistic basis is partially supported. Van Cauter et al. 1997 in JAMA showed that GH release and slow-wave sleep are tightly coupled, and that GH-releasing agents can amplify slow-wave sleep in some populations.<\/p>\n Whether CJC-1295 specifically improves sleep quality in healthy adults is unstudied. The closest evidence comes from sermorelin trials in adults with GH deficiency, which reported subjective sleep quality improvements but didn’t measure sleep architecture objectively.<\/p>\n Patients who report better sleep on CJC-1295 may be experiencing a real effect or a placebo response. We can’t distinguish from current data.<\/p>\n A controlled trial of CJC-1295 versus placebo in healthy middle-aged adults, with body composition, cardiometabolic outcomes, and subjective measures over at least 6 months, would address most of the gaps.<\/strong> None is currently registered on ClinicalTrials.gov.<\/p>\n A surveillance study of long-term CJC-1295 users in compounding pharmacy registries could provide observational safety data, particularly on cancer incidence. The infrastructure for this doesn’t exist in a way that would produce reliable data.<\/p>\n Pharmacovigilance data from the FDA’s MAUDE database for compounded peptide adverse events is limited but accessible. Anyone considering CJC-1295 long-term should know that the safety monitoring system that catches problems with FDA-approved drugs largely doesn’t exist for compounded peptides.<\/p>\n Bottom line: Sustained IGF-1 elevation is associated with increased cancer risk in epidemiology<\/p>\n Two published peer-reviewed trials, both run by ConjuChem in the mid-2000s. The longest trial lasted 28 days. By the standards applied to FDA-approved medications, the clinical trial backing is minimal.<\/p>\n The drug developer stopped development after a patient death in a separate Phase 2 trial. No commercial sponsor has had the incentive to fund large trials of a drug that lacks patent protection and exists in regulatory gray zones. Academic researchers occasionally study GHRH analogs, but most academic work has focused on tesamorelin and sermorelin where FDA approval exists.<\/p>\n The published research supports CJC-1295 as a drug that raises GH and IGF-1 for several days after a single dose. It doesn’t address whether this produces anti-aging benefits in any measurable outcome. The longevity epidemiology actually suggests lower IGF-1 is associated with longer lifespan, which is the opposite of what raising IGF-1 would predict.<\/p>\n Tesamorelin has roughly 100 times more published trial evidence and is FDA-approved. Sermorelin has decades of clinical use and was FDA-approved before being discontinued for commercial reasons. Recombinant GH has thousands of patient-years of trial data across multiple indications. CJC-1295 has the thinnest evidence base of the major GH-stimulating agents.<\/p>\n Long-term cancer risk. The biological mechanism, the epidemiology of IGF-1 and cancer, and the absence of surveillance data combine to make this the central unknown. Without long-term cohort data, anyone using CJC-1295 chronically is part of an uncontrolled experiment with themselves as the subject.<\/p>\n Skeptically. Many claims attributed to CJC-1295 in marketing materials trace back to tesamorelin trials or recombinant GH studies, not to published CJC-1295 data. The Teichman 2006 trial is small and short. Any prescriber or vendor making specific claims about body composition, anti-aging effects, or longevity should be able to cite the trial. If they can’t, the claim probably isn’t backed by published evidence.<\/p>\n As of 2026, no Phase 2 or Phase 3 trials of CJC-1295 are registered on ClinicalTrials.gov. A few small mechanistic studies appear periodically but none with the design or scale needed to address the major evidence gaps. The drug remains in regulatory and research limbo.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n <\/p>\n CJC-1295 has been in the peptide therapy conversation since the mid-2000s, but the published human evidence base is surprisingly small.<\/p>\n","protected":false},"author":11,"featured_media":92659,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"CJC-1295 What the Research Actually Says: Evidence Review","_yoast_wpseo_metadesc":"CJC-1295 has been in the peptide therapy conversation since the mid-2000s, but the published human evidence base is surprisingly small.","_yoast_wpseo_focuskw":"cjc 1295 research","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[19],"tags":[40,41],"class_list":["post-89261","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-longevity","tag-peptides","tag-research"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=89261"}],"version-history":[{"count":4,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89261\/revisions"}],"predecessor-version":[{"id":93660,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89261\/revisions\/93660"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/92659"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=89261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=89261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=89261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What Evidence Comes From Tesamorelin?<\/h2>\n
What’s the Evidence on Growth Hormone in Healthy Adults?<\/h2>\n
What Does the Cancer Epidemiology Show?<\/h2>\n
What Outcomes Have Never Been Studied?<\/h2>\n
How Does CJC-1295 Compare to GLP-1 Medication Evidence?<\/h2>\n
What About CJC-1295 and Longevity?<\/h2>\n
What Evidence Supports CJC-1295 for Sleep?<\/h2>\n
Where Does the Evidence Base Need to Go?<\/h2>\n
FAQ<\/h2>\n
Is CJC-1295 Backed by Clinical Trials?<\/h3>\n
Why Isn’t There More Research on CJC-1295?<\/h3>\n
Does the Research Support CJC-1295 for Anti-aging?<\/h3>\n
How Does CJC-1295 Evidence Compare to Peer Competitors?<\/h3>\n
What’s the Most Important Unanswered Question About CJC-1295?<\/h3>\n
Should Patients Trust Marketing Claims About CJC-1295?<\/h3>\n
Are There Ongoing CJC-1295 Trials?<\/h3>\n
Related Articles<\/h2>\n
\n